

9606166-8

Proposed Amendments

Amended sheet

Extra copy

-16-



What Is Claimed Is:

Replace with new Claim 1 ~~1. A method of treating or preventing acute myocardial infarction in a patient comprising the administration of ASA and hirudin.~~

Insert in new
Claim 2 →

3 2. ^{Use} ~~method~~ ^{or 2} of claim 1, wherein said ASA and said hirudin are separate unit dosage forms.

4 3. ^{Use} ~~method~~ ^{or 2} of claim 1, wherein said ASA and said hirudin are, together in a single unit dosage form.

5 4. ^{Use} ~~method~~ ^{or 2} of claim 1, wherein said patient is not being treated with a thrombolytic agent, is not used in the subject in need of such treatment.

10 ~~5. The method of claim 1, wherein said hirudin is selected from the group consisting of~~

(a) hirudin variant HV1 having the formula

Val Val Tyr Thr Asp Cys Thr Glu Ser Gly
Gln Asn Leu Cys Leu Cys Glu Gly Ser Asn
15 Val Cys Gly Gln Gly Asn Lys Cys Ile Leu
Gly Ser Asp Gly Glu Lys Asn Gln Cys Val
Thr Gly Glu Gly Thr Pro Lys Pro Gln Ser
His Asn Asp Gly Asp Phe Glu Glu Ile Pro

20

W
|
Glu Glu Tyr Leu Gln,

wherein W represents the phenolic hydroxy group of Tyr (desulfato hirudin HV1) or a group of the formula -O-SO₃H (hirudin HV1),

REPLACEMENT SHEET

26 JAN 1998



(b) ~~hirudin variant IFV2 having the formula~~

Ile Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys
Leu Cys Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys
Ile Leu Gly Ser Asn Gly Lys Gly Asn Gln Cys Val Thr Gly
Glu Gly Thr Pro Asn Pro Glu Ser His Asn Asn Gly Asp Phe
Glu Glu Ile Pro Glu Glu Tyr Leu Gln,

and

(c) hirudin variant PA having the formula


Ile Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys
Leu Cys Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys
Ile Leu Gly Ser Gln Gly Lys Asp Asn Gln Cys Val Thr Gly
Glu Gly Thr Pro Lys Pro Gln Ser His Asn Gln Gly Asp Phe
Glu Pro Ile Pro Glu Asp Ala Tyr Asp Glu.

6. The method of claim 1, wherein said hirudin is selected from the group consisting of (Ile^{1,2})-desulfato hirudin HV1, (Gly¹)-desulfato hirudin HV1, (Gln^{57,58,61,62})-desulfato hirudin HV1, (Pro⁶⁶)-desulfato hirudin HV1, (Gln²⁷, Arg⁴⁷)-desulfato hirudin HV1, (Met⁰, Gln²⁷, Arg⁴⁷)-desulfato hirudin HV1, (Gln²⁷, Gln³⁶, Arg⁴⁷)-desulfato hirudin HV1, (des-Val¹, Thr²)-desulfato hirudin HV1 and (Lys⁴⁷) hirudin HV2.

6. ^{Use} ~~The method~~ of claim 1, ^{or 2} wherein ^{the subject in need of such treatment is a} a human or animal ~~patient is~~ treated.

7-8. ^{Use} ~~The method~~ of claim 1, ^{or 2} wherein said ASA is given orally.

8-9. ^{Use} ~~The method~~ of claim 1, ^{or 2} wherein said hirudin is administered intravenously or subcutaneously.





9 10. A pharmaceutical composition comprising ASA and hirudin, ←

10 11. The pharmaceutical composition of claim 10⁹ additionally comprising one or more pharmaceutically acceptable carriers.

5 12. The pharmaceutical composition of claim 10⁹, wherein said pharmaceutical composition does not contain any thrombolytic agents.

10 ~~13. The composition of claim 10,~~ wherein said hirudin is selected from the group consisting of hirudin HV1, desulfato hirudin, (Ile^{1,2})-desulfato hirudin HV1, (Gly¹)-desulfato hirudin HV1, (Gln^{57,58,61,62})-desulfato hirudin HV1, (Pro⁶⁶)-desulfato hirudin HV1, (Gln²⁷, Arg⁴⁷)-desulfato hirudin HV1, (Met⁰, Gln²⁷, Arg⁴⁷)-desulfato hirudin HV1, (Gln²⁷, Gln³⁶, Arg⁴⁷)-desulfato hirudin HV1, (des-Val¹, Thr²)-desulfato hirudin HV1, hirudin HV2, (Lys⁴⁷)-hirudin HV2, and hirudin PA.

